Details
| Stereochemistry | MIXED |
| Molecular Formula | C11H15N3O5 |
| Molecular Weight | 269.2539 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N(CC2CO2)N(CC3CO3)C(=O)N1CC4CO4
InChI
InChIKey=ZTXDHEQQZVFGPK-UHFFFAOYSA-N
InChI=1S/C11H15N3O5/c15-10-12(1-7-4-17-7)11(16)14(3-9-6-19-9)13(10)2-8-5-18-8/h7-9H,1-6H2
Anaxirone is a triepoxide compound with cytotoxic activity. By analogy with bifunctional epoxides, anaxirone probably acts as an alkylating agent. Despite a wide spectrum of activity against experimental tumors in rats and mice, clinical investigation of anaxirone has shown that the drug was inactive for the treatment of advanced colorectal cancer, advanced soft tissue sarcoma, small cell lung cancer, ovarian cancer, and advanced malignant melanoma.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| alpha-/beta-Triglycidyl-urazol (TGU, NSC 332488, I.N.N.: ANAXIRONE): a new chemotherapeutic agent. | 1984 Jun |
|
| Phase II trial of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma. | 1987 Feb |
|
| Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer. | 1987 Jul |
|
| Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study. | 1987 Jun |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C475
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
||
|
NCI_THESAURUS |
C574
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C041113
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105991
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
278-745-8
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
332488
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
77658-97-0
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
100000086920
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
SUB05503MIG
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
71218
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
DTXSID10868451
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
5629
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
C950
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY | |||
|
36R61Y789T
Created by
admin on Fri Dec 15 15:37:07 GMT 2023 , Edited by admin on Fri Dec 15 15:37:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
